To test this hypothesis, PBMC from CLL patients were incubated with or without aCD3 in the presence of DMSO, SKI-II or opaganib for 72 h and the survival of CD4+ and CD8+ T cells was evaluated by flow cytometry. Here, CD8A is linked to B-cell chronic lymphocytic leukemia.